Pharmaceutical

BeiGene to acquire DualityBio’s ADC therapy for solid tumours

BeiGene has signed an agreement with DualityBio for the acquisition of an exclusive licence for an ADC therapy to treat solid tumours.

Jul 11, 2023 - 20:00
BeiGene to acquire DualityBio’s ADC therapy for solid tumours
BeiGene has signed an agreement with DualityBio for the acquisition of an exclusive licence for an ADC therapy to treat solid tumours.
Read the original article

Tags:

Previous Article

Astellas licenses 4DMT’s AAV vector for ophthalmic targets

Next Article

Elsie and GSK link to accelerate oligonucleotide discovery platform

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Tonix to acquire Upsher-Smith’s migraine products

Tonix to acquire Upsher-Smith’s migraine products

Jun 27, 2023

Key questions (and answers) about the historic approval of a CRISPR-based medicine

Key questions (and answers) about the historic approval...

Nov 17, 2023

Opinion: A roadmap for making over-the-counter birth control affordable

Opinion: A roadmap for making over-the-counter birth co...

Aug 23, 2023